Previous 10 | Next 10 |
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
The Ligand and SEEL Partnership On September 22, 2016, Ligand Pharmaceuticals Incorporated (LGND), a $2.6 Billion public company, announced the licensing of rights to four programs to Seelos Therapeutics, Inc. (SEEL), a newly formed company focused on the central nervous system. Accord...
ZULRESSO is the first and only treatment specifically indicated for postpartum depression Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of ...
It has only been a few months since my first Seelos article ( SEEL ), but the company has been negotiating two deals to expand its pipeline and areas of study. The first deal was made in February with Bioblast Pharma ( ORPN ) concerning their mutant protein stabilization solution called Treh...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Barclays Global Healthcare Conference in Miami. Presentation takes place on Wednesday, March 13, 2019 at 9:00 a.m. Eastern...
COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer Dr. David Portman will ...
Investors appear disappointed with Ligand Pharmaceuticals' ( LGND -11.6% ) agreement to sell its rights to Promacta (eltrombopag) to Royalty Pharma for $827M in cash. The company plans to reinvest the proceeds to acquire assets with long-term revenue streams, fully funded "shots o...
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 66 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This i...
Updates 2019 full-year financial guidance Conference call with slides to be held today at 5:00 p.m. Eastern time Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand’s Promacta ® -related intellectual property rights lice...
COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced it will present a poster on the performance of its lead investig...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-08-02 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...